Dr at Gustave Roussy
Gustave Roussy cancer campus
Paris, Ile-de-France, France
I have a mixed clinical and scientific training in paediatric oncology (Paris, France) and in preclinical drug development (Institute of cancer research, UK).
I'm the head of the adolescent unit and chair of the adolescent and young adult (AYA) programme of the institute (SPIAJA program), since 2009 (https://www.gustaveroussy.fr/fr/ adolescents-jeunes-adultes-equipe). I am much involved at national and European level, in AYA care (member of the French GO-AJA association and of the ESMO-SIOPE AYA educational working group); and in early drug development through my implication in the Innovative Therapeutics for Child and adolescent with Cancer (ITCC) consortium (http://www.itcc-consortium.org/). I am co-chairing with Chris Copland (UK) a parent representative, the ACCELERATE Fostering Age Inclusive Research (FAIR) trial group (https://www.accelerate-platform.eu/work-programme/ongoing/working-group-fair/).
My main focus in term of disease are typical AYA cancers, especially bone sarcomas from biology to clinic. I am the paediatric head of the French bone sarcoma group, GROUPOS, since 2018. I am leading the national programme of French osteosarcoma clinical, biological, genomic and radiomic database for data sharing, BoOST-DataS (https://www.gustaveroussy.fr/en/boost-datas). I am in charge of the Biological and bioinformatics Osteosarcoma team (BiiOSTeam, U1015) at Gustave Roussy with Antonin MARCHAIS (researcher bioinformatician). I am PI of national and international therapeutic trials to fight osteosarcoma (Sarcoma13, OLIE) and Ewing sarcoma, from diagnosis to relapse. I am part of the executive committee of the Euro-Ewing consortium (EEC) and used to work harmoniously with Sandra STRAUSS in this context. I am board member of the EMSOS society, and co-chair of the transatlantic HiBisCus, bone sarcoma part of pediatric cancer data common sharing project.
I am chairing the FOSTER (Fight Osteosarcoma Through European Research) consortium to bring together all osteosarcoma specialists, professionals, patients and parents, to ultimately improve patient outcome and quality of live.
Disclosure information not submitted.
Friday, November 3, 2023
11:30 AM – 12:30 PM
Paper 51 - TUMOR CELL PLASTICITY DEFINE OSTEOSARCOMA SUBTYPES
Friday, November 3, 2023
2:30 PM – 4:00 PM
Session 8: Adolescent and Young Adult Sarcomas
Friday, November 3, 2023
2:30 PM – 4:00 PM